These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 19088258

  • 1. Just released from the ASAS factory! First steps towards a disease activity score for ankylosing spondylitis.
    Boers M.
    Ann Rheum Dis; 2009 Jan; 68(1):1-2. PubMed ID: 19088258
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. High disease activity of ankylosing spondylitis in the community before the introduction of tumour necrosis factor blockers.
    Hermann J, Müller T, Yazdani-Biuki B, Aringer M, Herold M, Ebner W, Ofner P, Graninger W.
    Ann Rheum Dis; 2007 Apr; 66(4):561-2. PubMed ID: 17360786
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Repeated cyclosporine therapy of peripheral arthritis associated with ankylosing spondylitis.
    Géher P, Gömör B.
    Med Sci Monit; 2001 Apr; 7(1):105-7. PubMed ID: 11208503
    [Abstract] [Full Text] [Related]

  • 13. TNF inhibitors for ankylosing spondylitis in the real world.
    McVeigh CM, Bell AL, Cairns AP.
    Rheumatol Int; 2007 Dec; 28(2):199-200. PubMed ID: 17602229
    [No Abstract] [Full Text] [Related]

  • 14. [Revised recommendations of the Deutsche Gesellschaft für Rheumatologie on therapy with tumor necrosis factor-inhibiting active substances on inflammatory diseases].
    Manger B, Kommission Pharmkotherapie, Deutsche Gesellschaft für Rheumatologie.
    Z Rheumatol; 2002 Dec; 61(6):694-7. PubMed ID: 12491133
    [No Abstract] [Full Text] [Related]

  • 15. Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction?
    Schett G, Landewé R, van der Heijde D.
    Ann Rheum Dis; 2007 Jun; 66(6):709-11. PubMed ID: 17513569
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?
    Gaspersic N, Sersa I, Jevtic V, Tomsic M, Praprotnik S.
    Ann Rheum Dis; 2008 Sep; 67(9):1354. PubMed ID: 18697784
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Tuberculous peritonitis.
    Finlay DG, Szauter K, Raju GS, Snyder N.
    Am J Gastroenterol; 2005 Jul; 100(7):1624-5. PubMed ID: 15984997
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.